NGLFINENSENGL Fine-Chem Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 3 Feb, 2026 · 20:09 IST

NGL Fine-Chem Q3 FY26: revenue up 43% YoY, profit jumps sharply

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

NGLFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+19.0%Reaction day
₹1818.30
prior close
₹2050.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+17.7% vs market
Pharmaceuticals peers, median of 155sector+0.2%+18.8% vs sector

On the reaction day the stock moved 17.7 pts more than Nifty Microcap 250 and 18.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+4.1
10m
+5.6
15m
+5.6
30m
+5.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+19.0+1.3+17.7+0.2+18.8
Next day
+24.8+0.3+24.5-0.4+25.2
2d
+18.8-0.5+19.3-1.1+19.9
3d
+22.4+2.1+20.3+0.7+21.7
4d
+21.4+3.1+18.3+1.3+20.1
5d
+23.1+2.6+20.5+1.4+21.7
1w
+26.5+0.6+25.9+0.3+26.2
15d
+24.0-1.4+25.4-2.6+26.6
1m
+25.9-6.9+32.9-5.1+31.0
2m
+22.6-7.7+30.3-7.9+30.6
3m
+21.3+7.0+14.3+0.7+20.6
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NGL Fine-Chem reported Q3 FY26 consolidated revenue of Rs 127.51 crore, up 43% YoY from Rs 89.10 crore. Nine-month revenue rose 29% to Rs 351.89 crore. Profit after tax jumped to Rs 15.69 crore from Rs 1.28 crore in Q3 FY25. Nine-month PAT stood at Rs 34.56 crore, up 70% YoY. Standalone numbers were similar. Board appointed Mr. Shivam Gharat as new Company Secretary. Statutory auditor issued a clean limited review report with no qualifications.

Likely market impact

Strong revenue and profit growth signal improving business momentum. Clean audit and robust numbers likely positive for stock sentiment.